Binding of phosphatidylserine-positive microparticles by PBMCs classifies disease severity in COVID-19 patients
L. Rausch, K. Lutz, M. Schifferer, E. Winheim, R. Gruber, L. Rinke, J. Hellmuth, C. Scheerer, M. Muenchhoff, C. Mandel, M. Bergwelt-Baildon, M. Simons, T. Straub, A. B. Krug, J. Kranich, T. Brocker
The paper identifies PS+ PMPs as a marker for disease severity in COVID-19 by showing their correlation with immune dysfunction and clinical outcomes.
bioRxiv · Jun 18, 2021Immunology